Payment overview · 2025
General Payments
$2,147.60
98 reported records · 32 companies
Healthcare provider profile · identity verified
Jennifer Edgar, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · EAST LANSING, MI · NPI 1174975262
Verified facts
What the public records show
CMS Open Payments records show Jennifer Edgar, NP-C received $2,147.60 in general payments during 2025 across 98 reported records.
Amneal Pharmaceuticals LLC accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Epidiolex, Fycompa, Nayzilam.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Rytary by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Fycompa by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EPIDIOLEX as an associated drug or biological on 10990 records involving 3626 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Epidiolex by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Briviact by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $341.30 | 15.9% | 18 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $265.26 | 12.3% | 12 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $214.89 | 10.0% | 13 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $91.08 | 4.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $80.93 | 3.8% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.88 | 3.7% | 3 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $75.09 | 3.5% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $74.96 | 3.5% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.35 | 3.5% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $73.37 | 3.4% | 3 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.52 | 3.1% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$64.57 | 3.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $62.20 | 2.9% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.45 | 2.6% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.49 | 2.4% | 2 | 2025 |
| Otter Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $49.62 | 2.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.75 | 2.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.62 | 1.8% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $38.96 | 1.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.41 | 1.6% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$30.65 | 1.4% | 2 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $29.15 | 1.4% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $27.09 | 1.3% | 1 | 2025 |
| UPSHER-SMITH LABORATORIES LLC | Unresolved — no canonical attribution shown | $26.54 | 1.2% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $24.46 | 1.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$24.03 | 1.1% | 1 | 2025 |
| HOSPIRA, INC. | Unresolved — no canonical attribution shown | $19.86 | 0.9% | 1 | 2025 |
| ITF Therapeutics LLC | Unresolved — no canonical attribution shown | $19.51 | 0.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.86 | 0.8% | 1 | 2025 |
| Cala Health, Inc. | Unresolved — no canonical attribution shown | $17.78 | 0.8% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $16.58 | 0.8% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $16.39 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,147.60 | 98 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $341.30 | 18 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $143.89 | 7 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $91.08 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $80.93 | 3 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $79.88 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $74.96 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $74.35 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $73.37 | 3 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $67.52 | 3 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | HOSPIRA, INC., Octapharma USA, Inc., PFIZER INC. | $66.87 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $62.20 | 2 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $55.45 | 2 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $54.42 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $51.49 | 2 | 2025 |
Source payment records
|
|||||
| SYMPAZAN Normalized: sympazan |
Drug | Otter Pharmaceuticals, LLC | $49.62 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $42.75 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $40.76 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.62 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.62 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $36.12 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $34.41 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $30.65 | 2 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| VIGADRONE Normalized: vigadrone |
Drug | UPSHER-SMITH LABORATORIES LLC | $26.54 | 1 | 2025 |
Source payment records
|
|||||
| VIGAFYDE Normalized: vigafyde |
Drug | UPSHER-SMITH LABORATORIES LLC | $26.54 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | HOSPIRA, INC. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| Cala kIQ Normalized: cala kiq |
Device | Cala Health, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka Pharmaceutical Development & Commercialization, Inc. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 191 | exact normalized | Medicare Part D |
| EPIDIOLEX epidiolex |
2025 | Epidiolex | 2024 | 61 | exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Nayzilam nayzilam |
2025 | Nayzilam | 2024 | 26 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
87 | 28 |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | EPIDIOLEX open payments reported associated product |
CMS Open Payments — General Payments 10990 supporting records · 3626 recipient NPIs · example record 1234297758 |
Epidiolex · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
91 | 21 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
191 | 34 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
26 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 288 | 94 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 252 | 99 |
| Lamotrigine | Lamotrigine | 227 | 64 |
| Lacosamide | Lacosamide | 204 | 61 |
| Briviact | Brivaracetam | 191 | 34 |
| Zonisamide | Zonisamide | 142 | 40 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 111 | 43 |
| Gabapentin | Gabapentin | 105 | 32 |
| Clonazepam | Clonazepam | 95 | 28 |
| Divalproex Sodium | Divalproex Sodium | 93 | 15 |
| Xcopri | Cenobamate | 91 | 21 |
| Clobazam | Clobazam | 88 | 21 |
| Rytary | Carbidopa/Levodopa | 87 | 28 |
| Epidiolex | Cannabidiol (Cbd) | 61 | 13 |
| Aptiom | Eslicarbazepine Acetate | 57 | suppressed |
| Topiramate | Topiramate | 53 | 19 |
| Oxcarbazepine | Oxcarbazepine | 51 | 12 |
| Lorazepam | Lorazepam | 50 | 12 |
| Donepezil Hcl | Donepezil Hcl | 43 | 18 |
| Lamotrigine Er | Lamotrigine | 42 | 11 |
| Primidone | Primidone | 42 | 16 |
| Phenobarbital | Phenobarbital | 39 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Levetiracetam Er | Levetiracetam | 35 | 14 |
| Methylphenidate Hcl | Methylphenidate Hcl | 30 | suppressed |
| Rivastigmine | Rivastigmine | 29 | 11 |
| Amantadine | Amantadine Hcl | 26 | 14 |
| Nayzilam | Midazolam | 26 | 13 |
| Baclofen | Baclofen | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Ingrezza | Valbenazine Tosylate | 22 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 22 | suppressed |
| Fycompa | Perampanel | 21 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Neupro | Rotigotine | 17 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Keppra | Levetiracetam | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Tegretol Xr | Carbamazepine | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 12 | suppressed |
| Lamictal | Lamotrigine | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,147.60 · 98 records | Amneal Pharmaceuticals LLC | AMYVID, BRIUMVI, Briviact, CREXONT, Cala kIQ, DAYBUE, EPIDIOLEX, FIRDAPSE, FYCOMPA, Fintepla, HYQVIA, KESIMPTA, KISUNLA, Leqembi, Motpoly XR, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), ONPATTRO, Ocrevus Zunovo, PANZYGA, PERCEPT PC BRAINSENSE, PONVORY, QULIPTA, QUTENZA, Qelbree, REXULTI, Radicava, Rystiggo, SYMPAZAN, Symbravo, UBRELVY, ULTOMIRIS, VALTOCO, VIGADRONE, VIGAFYDE, VYEPTI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error